SAN FRANCISCO – Accelerated approval from FDA is rare in immunology, but this is an underutilized pathway that might be further explored in the therapeutic area in the future, Genentech Inc.’s Jeffrey Siegel said in a recent interview.
Genentech’s Siegel: Why Not More Accelerated Approvals In Immunology?
Podcast – A former FDA official now at Genentech, Jeffrey Siegel talks about unmet need in rheumatology and potential opportunities with the agency for speeding things up outside of oncology.